A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

The protocol was originally designed as a Simon two stage but after it was determined that
the initial 13 patients enrolled did not meet the definition of a 'responder' according to
the International Uniform Response Criteria for multiple myeloma the protocol was amended to
allow patients who had disease progression at any time or stable disease for 3 cycles and did
not meet a withdrawal criterion or had withdrawn consent to have 40 mg of dexamethasone added
to their dose of ruxolitinib.

Inclusion Criteria:

- Confirmed diagnosis of multiple myeloma with evidence of measurable disease.

- Relapsed or refractory disease with at least one line of prior therapy.

- Adequate bone marrow reserve.

Exclusion Criteria:

- Received anti-cancer medications or investigational therapy in the past 28 days.

- Intracranial disease or epidural disease.